An important risk factor for relapse to smoking is female gender. Women have less success in unaided quit attempts and may be less responsive to nicotine replacement therapies than men. Higher stress reactivity and prevalence of mood-related symptoms are increasingly recognized as important for the increased difficulty in quitting experienced by women. Both norepinephrine and acetylcholine are critical neurotransmitters regulating activity in brain circuits essential for stress-related behaviors, including the amygdala-prefrontal cortical circuit. In keeping with the overarching theme ofthe Yale-SCOR related to sex differences in noradrenergic control of smoking behavior, we hypothesize that the disparity in susceptibility to smoking relapse between women and men may be due to underlying differences in cholinergic- noradrenergic interactions. Thus, it is important to examine these mechanisms in an animal model with input and feedback from Projects II and III to determine what alterations in neurochemistry might underlie these differences and to provide an integrated understanding ofthe neurobiological basis for sex differences in smoking. The primary aims of Project I are to identify the brain areas regulated by guanfacine and nicotinic drugs under conditions related to stress-reactivity (Aim 1), to determine whether stimulation ofthe noradrenergic system with guanfacine can decrease stress reactivity (Aim 2) and dopamine dependent behaviors (Aim 3) in a hypercholinergic model of increased stress reactivity in male and female mice. This project will also determine whether the effects of guanfacine on anxiety and nicotine reinforcement depend on expression of nAChRs (Aim 4). This basic science project is designed to identify neuronal mechanisms underlying similar effects of guanfacine to decrease smoking in female and male human subjects, but to decrease stress reactivity only in women. It is also designed to identify neurochemical mechanisms underlying the effects of guanfacine on the cholinergic and dopaminergic systems. The findings from Project I will be integrated with those from Projects II and III of the Yale-SCOR to inform the development of novel gender-sensitive therapeutics for smoking cessation

Public Health Relevance

; Tobacco smoking is the most significant preventable cause of death. Despite availability of therapies, women are more likely to relapse to smoking when they try to quit. Stress reactivity in women could be responsible for this difference. The noradrenergic medication guanfacine helps women resist stress-induced relapse and helps women and men quit smoking. Understanding the neurobiology underlying these effects could pave the way for more tailored therapies for smoking cessation in women and men.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA033945-02
Application #
8501388
Study Section
Special Emphasis Panel (ZRG1-EMNR-Q)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$324,301
Indirect Cost
$154,015
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Park, Crystal L; Finkelstein-Fox, Lucy; Barnes, David M et al. (2016) CAM use in recently-returned OEF/OIF/OND US veterans: Demographic and psychosocial predictors. Complement Ther Med 28:50-6
Allen, Alicia M; McRae-Clark, Aimee L; Carlson, Samantha et al. (2016) Determining menstrual phase in human biobehavioral research: A review with recommendations. Exp Clin Psychopharmacol 24:1-11
Smith, Philip H; Oberleitner, Lindsay M S; Smith, Kathryn M Z et al. (2016) Childhood adversity interacts with adult stressful events to predict reduced likelihood of smoking cessation among women but not men. Clin Psychol Sci 4:183-193
Lewis, Alan S; Oberleitner, Lindsay M S; Morgan, Peter T et al. (2016) Association of Cigarette Smoking With Interpersonal and Self-Directed Violence in a Large Community-Based Sample. Nicotine Tob Res 18:1456-62
Mazure, Carolyn M (2016) Our evolving science: studying the influence of sex in preclinical research. Biol Sex Differ 7:15
Smith, Philip H; Bessette, Andrew J; Weinberger, Andrea H et al. (2016) Sex/gender differences in smoking cessation: A review. Prev Med 92:135-140
Verplaetse, Terril L; Smith, Philip H; Pittman, Brian P et al. (2016) Associations of Gender, Smoking, and Stress with Transitions in Major Depression Diagnoses. Yale J Biol Med 89:123-9
McKee, Sherry A; Smith, Philip H; Kaufman, Mira et al. (2016) Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine Tob Res 18:1002-11
Mineur, Yann S; Fote, Gianna M; Blakeman, Sam et al. (2016) Multiple Nicotinic Acetylcholine Receptor Subtypes in the Mouse Amygdala Regulate Affective Behaviors and Response to Social Stress. Neuropsychopharmacology 41:1579-87
Mazure, Carolyn M; Swendsen, Joel (2016) Sex differences in Alzheimer's disease and other dementias. Lancet Neurol 15:451-2

Showing the most recent 10 out of 66 publications